Relief Therapeutics
About Relief Therapeutics
Relief Therapeutics aims to become a key player in the biotechnology and pharmaceutical industry.We will provide patients with therapeutic relief from diseases for which high needs persist.
We strongly believe that only by effectively treating patients will our investors realize significant return on investment.
Our areas of interest cover a broad range of indications from niche (orphan indications) up to larger markets.
Our experimental drugs are primarily of natural origin and have been already tested or used safely in the clinical setting thereby minimizing risks and maximizing efficacious potential.
Relief focuses on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decisive results.
YEAR FOUNDED:
1956
LEADERSHIP:
CEO: Raffaele Petrone
CFO: Tim Snyder
COO: Gael Hedou
CSO: Yves Sagot
Chief Business Officer: Michel Dreano
Chief Development Officer: Dorian Bevec
233 articles about Relief Therapeutics
-
Clinical Catch-Up: May 11-15
5/18/2020
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look. -
Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
5/14/2020
Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilation
-
Relief Therapeutics Announces Filing of IND for Phase 2/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury
5/11/2020
Study to enroll 144 patients with COVID-19-associated non-acute lung injury in an attempt to decrease progression to Acute Respiratory Distress Syndrome and need for ICU care
-
Relief Therapeutics Holding (RLF:SIX) Drug Aviptadil Enters FDA Trial at NYU Langone Health, New York, to Treat COVID-19-Induced Acute Respiratory Distress
5/6/2020
Aviptadil targets the cytokine storm that causes fatal Respiratory Distress in COVID-19
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
-
Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at Thomas Jefferson University Hospital in Philadelphia, to Treat COVID-19-induced Acute Respiratory Distress
4/9/2020
RELIEF THERAPEUTICS Holding AG “Relief” announces that its drug Aviptadil has now entered FDA clinical trials at Thomas Jefferson University Hospital in Philadelphia for the treatment of Acute Respiratory Distress Syndrome in COVID-19.
-
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
3/26/2020
Aviptadil is a patented synthetic form of Vasoactive Intestinal Polypeptide that has previously shown promise in treating ARDS - Coronavirus (COVID-19) death is primarily caused by Acute Respiratory Distress Syndrome (ARDS), in which severe inflammation causes the lungs to fill with fluid and even mechanical ventilation is unable to maintain life. The syndrome is caused by a Cytokine Storm unleashed by viral particles. - VIP is known to have potent anti-cytokine effects in nu
-
RELIEF THERAPEUTICS HOLDING SA (SIX: RLF) Announces Plans to Test Aviptadil for the Treatment of COVID-induced Acute Respiratory Distress Syndrome (ARDS)
3/17/2020
Compassionate care protocol to be conducted at Rambam Healthcare Campus in coordination with the Government of Israel
-
RELIEF THERAPEUTICS Holding SA (SIX: RLF) announces the proposal of Prof. Jonathan Javitt, M.D., M.P.H., at the upcoming general assembly as Vice Chairman of the Board
3/11/2020
Javitt to guide development of RLF-100 (Aviptadil) for treatment of Coronavirus (COVID-19) induced Acute Respiratory Distress Syndrome
-
Swiss Biotech Relief Therapeutics to Consolidate Offices and Cut Jobs, CEO and CFO Step Down
2/20/2017
-
Relief Therapeutics And FirstString Research Announce A Strategic Collaboration For The Development Of Atexakin Alfa
10/25/2016
-
PX’Therapeutics And Relief Therapeutics Announce A Strategic Collaboration Agreement For The Recombinant Production Of Atexakin Alfa
10/6/2016
-
Relief Therapeutics Announces Signing of a Term Sheet to Acquire FirstString Research, Inc.
7/28/2016